Zai Lab LtdZLAB

時価総額

$299.4億

PER

バイオ医薬品の有力企業。オンコロジーを中心とした研究開発と商用化済み製品7件を展開。2019年のDeciphera契約や2021年のargenx提携などのライセンス実績。中国本土・香港・マカオ中心の展開。

	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Cash and cash equivalents	230	63	76	442	964	1,008	790	450
Restricted cash, current	-	-	-	-	-	-	-	100
Short-term investments	-	200	200	745	445	-	16	330
Accounts Receivable, after Allowance for Credit Loss, Current	-	89,708	4	5	47	40	59	85
Notes receivable	-	-	-	-	-	9	6	4
Inventory, Net	-	3,822	6	13	19	32	45	40
Prepayments and other current assets	954,506	6	7	11	18	36	23	42
Total current assets	231	269	292	1,216	1,501	1,124	940	1,050
Restricted Cash, Noncurrent	-	-	1	1	1	1	1	1
Long-term investments	2	3	2	1	16	6	9	3
Prepayments for equipment	126,411	275,853	0	0	1	1	0	0
Property and equipment, net	12	20	21	29	43	58	54	48
Operating lease right-of-use assets	-	-	15	18	14	20	15	21
Land use rights, net	-	-	8	8	8	7	3	3
Intangible assets, net	20,089	321,566	1	2	2	2	13	56
Long-term deposits	306,825	556,738	0	1	1	1	1	1
Value added tax recoverable	5	8	14	22	24	-	-	1
Total assets	250	302	355	1,298	1,610	1,220	1,036	1,186
Accounts payable	9	37	23	63	126	66	113	101
Current operating lease liabilities	-	-	4	5	6	7	7	8
Short-term debt	-	4	6	-	-	-	-	132
Other current liabilities	3	8	13	30	61	67	83	59
Total current liabilities	12	49	47	98	193	140	203	299
Deferred income	-	-	-	-	-	21	29	31
Operating Lease, Liability, Noncurrent	-	-	11	13	10	13	8	14
Other non-current liabilities	-	-	-	-	-	-	0	0
Total liabilities	14	51	60	128	230	175	240	345
Common Stock, Value, Issued	2,995	3,481	0	0	0	0	0	0
Additional paid-in capital	345	498	735	1,897	2,826	2,893	2,975	3,264
Accumulated deficit	-110,551,613	-249,626,508	-445	-714	-1,418	-1,861	-2,196	-2,453
Accumulated other comprehensive income	449,908	3	5	-15	-24	26	38	51
Treasury stock (at cost, 4,912,200 shares as of both December 31, 2024 and 2023)	-	-	-	-	-	12	21	21
Total shareholders’ equity	235	251	295	1,169	1,380	1,046	796	841
Total liabilities and shareholders’ equity	250	302	355	1,298	1,610	1,220	1,036	1,186